OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kim on Optimizing Outcomes With Molecular Profiling in mCRC

December 13th 2019

Richard Kim, MD, discusses how molecular profiling can be used to optimize outcomes in patients with metastatic colorectal cancer.

Dr. Saxena on Treatment Options in ALK+ NSCLC

December 13th 2019

Ashish Saxena, MD, PhD, discusses the treatment landscape of ALK-positive non–small cell lung cancer.

Dr. Unger on Utilizing a Multidisciplinary Team in Gastroesophageal Cancer

December 13th 2019

Keith R. Unger, MD, discusses utilizing a multidisciplinary team to treat patients with gastroesophageal cancer.

Dr. Msaouel on Rationale for Sitravatinib/Nivolumab Combo in Urothelial Cancer

December 13th 2019

Pavlos Msaouel, MD, PhD, discusses the rationale for a phase II study evaluating sitravatinib in combination with nivolumab in patients with metastatic or advanced urothelial cancer.

Dr. Marron on Shortening Treatment Duration of Immunotherapy in Melanoma

December 12th 2019

Thomas Marron, MD, PhD, discusses the potential benefit of shortening the length of immunotherapy treatment in melanoma.

Dr. Fowler on Types of Surgical Procedures in Ovarian Cancer

December 12th 2019

Jeffrey M. Fowler, MD, discusses the various types of surgical procedures in ovarian cancer.

Dr. Drilon on Treatment Selection Considerations in ALK+ NSCLC

December 12th 2019

Alexander Drilon, MD, discusses what factors he considers when selecting treatment for patients with ALK fusion-positive non–small cell lung cancer.

Dr. Rule on Long-Term Follow-Up of Ibrutinib Monotherapy in Relapsed/Refractory MCL

December 11th 2019

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

Dr. Hays on Potential for PARP Inhibitor Combinations in Ovarian Cancer

December 11th 2019

John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.

Dr. Eradat on Rituximab Biosimilar in CD20+ B-Cell Non-Hodgkin Lymphoma and CLL

December 10th 2019

Herbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Corcoran on the Utility of Regorafenib in CRC

December 10th 2019

Ryan B. Corcoran, MD, PhD, discusses the utility of regorafenib in colorectal cancer.

Dr. Parikh on KRAS Inhibitors in Lung Cancer

December 10th 2019

Kaushal Parikh, MD, MBBS, discusses the KRAS inhibitors AMG 510 and MRTX849 in lung cancer.

Dr. Bowman on Rationale for Radio-Labeled Atezolizumab PET/CT Scans in RCC

December 10th 2019

I. Alex Bowman, MD, discusses the rationale for an exploratory clinical trial of radio-labeled 89Zr-atezolizumab PET/CT scans in renal cell carcinoma.

Dr. Perales on the Future of CAR T-Cell Therapy in DLBCL and Follicular Lymphoma

December 10th 2019

Miguel-Angel Perales, MD, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Dr. Smith on the Rationale Behind the Fixed Duration Trial for Ibrutinib/Venetoclax in CLL

December 10th 2019

Mitchell R. Smith, MD, PhD, discusses the rationale behind the trial looking at the fixed duration of the ibrutinib and venetoclax combination in chronic lymphocytic leukemia.

Dr. Benson on MSI Testing in Colorectal Cancer

December 10th 2019

Al B. Benson, MD, discusses the implications of microsatellite instability testing on patients with colorectal cancer.

Dr. Vaishampayan on Immunotherapy in mRCC

December 10th 2019

Ulka Vaishampayan, MD, discusses the utility of immunotherapy in metastatic renal cell carcinoma.

Dr. Rizk on Eligibility Criteria for Surgical Resection in Lung Cancer

December 10th 2019

Nabil P. Rizk, MD, MS, MPH, discusses criteria for surgical resection in lung cancer.

Dr. Ilson Discusses Challenges with Immunotherapy in Gastric Cancer

December 10th 2019

David H. Ilson, MD, PhD, discusses remaining challenges with immunotherapy in gastric cancer.

Dr. Catenacci on Treatment Selection in Esophagogastric Junction Adenocarcinoma

December 7th 2019

Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.